STOCK TITAN

Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Kazia Therapeutics (KZIA) filed its annual report on Form 20-F with the SEC for the fiscal year ended June 30, 2026. Cash, cash equivalents and short-term investments totaled approximately A$61.2 million at fiscal year-end. Kazia believes working capital, August 2026 offering proceeds and the September 2026 Sovargen milestone payment can fund planned operations for at least 12 months from the annual report date.

The offering generated approximately US$40 million in upfront gross proceeds, with up to approximately US$80 million more in gross proceeds from warrants tied to trial readouts. Initial data from paxalisib-based regimens in six evaluable patients with stage IV triple-negative breast cancer showed a 100% clinical benefit rate and an 83% objective response rate. First dosing in Sovargen's epilepsy trial triggered a US$2 million milestone payment to Kazia.

Loading...
Loading translation...
13 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointAugust 2026 public offering generated approximately US$40 million in upfront gross proceeds 47% of market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Planned operations can be funded for at least 12 months from the annual report date, Kazia believes
  • Moderate pointSovargen milestone payment brought Kazia US$2 million in September 2026 after first dosing in Sovargen's epilepsy trial 2.3% of market cap
  • Minor pointInitial stage IV triple-negative breast cancer data showed a 100% clinical benefit rate and 83% objective response rate in six evaluable patients
  • Minor pointInitial safety findings showed no serious adverse events related to paxalisib in the stage IV triple-negative breast cancer data
8 minor points
  • Minor pointBreast cancer trial expansion is advancing with three groups for hormone receptor-positive, HER2-negative disease
  • Minor point. Forward-looking: it has not happened yet and may not happen.Five-group Phase 2 colorectal cancer study is planned for MSS/pMMR disease, with enrollment expected to begin in Q1 2027
  • Minor pointFirst dosing in PNOC035 Arm A advanced testing of paxalisib plus gemcitabine in recurrent or progressive pediatric AT/RT, a brain tumor
  • Minor pointFirst dosing in Sovargen's Phase 1b/2a trial advanced testing of paxalisib in rare mTORopathy-related epilepsies
  • Minor pointMetastasis-associated circulating tumor cell clusters showed a median reduction of 83% in the initial breast cancer data
  • Minor pointTerminally exhausted CD8+ T cells showed a median reduction of 51% in the initial breast cancer data
  • Minor pointThree provisional patent applications cover paxalisib treatment strategies in triple-negative breast cancer, drug-resistant hormone receptor-positive breast cancer and colorectal cancer
  • Minor pointPreclinical findings showed a 95% reduction in residual disease and local recurrence (p<0.0001) after preoperative chemo-immunotherapy and surgery

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Milestone-linked warrants can dilute existing shareholders if exercised
  • Minor point. Forward-looking: it has not happened yet and may not happen.Up to approximately US$80 million in additional gross proceeds is tied to warrants linked to stage IV triple-negative breast cancer and hormone receptor-positive, HER2-negative breast cancer readouts expected in 2H 2027 and 1H 2028, respectively

Key Figures

Cash, cash equivalents and short-term investments: approximately A$61.2 million Planned-operations funding period: at least 12 months Clinical benefit rate: 100% +5 more
Cash, cash equivalents and short-term investments
approximately A$61.2 million
As of 30 June 2026
Planned-operations funding period
at least 12 months
From the Annual Report date
Clinical benefit rate
100%
Stage IV TNBC; six evaluable patients treated with paxalisib-based regimens
Objective response rate
83%
Stage IV TNBC; six evaluable patients treated with paxalisib-based regimens
Median reduction in metastasis-associated CTC clusters
83%
Stage IV TNBC data
Median reduction in terminally exhausted CD8+ T cells
51%
Stage IV TNBC data
Upfront gross proceeds
Approximately US$40 million
Public offering
Additional gross proceeds from milestone-linked warrants
Up to approximately US$80 million
Tied to the Stage IV TNBC and HR+/HER2- data readouts

Historical Context

1 past event · Latest: Sep 22
1 event
  1. Sep 22

    Sovargen trial milestone

    24h Move
    +2.5%

    First-patient dosing triggered a $2 million milestone, later reported received in September.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 20-f, tnbc, objective response rate, serious adverse events
4 terms
form 20-f regulatory
"filed its Annual Report on Form 20-F for the fiscal year ended June 30, 2026"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
tnbc medical
"Encouraging initial Stage IV TNBC data"
A subtype of breast cancer that lacks three common treatment targets — the hormone receptors for estrogen and progesterone, and the HER2 protein — so standard targeted medicines usually won’t work. Think of it like a door with none of the usual keyholes, meaning doctors rely on chemotherapy, new targeted drugs, or immunotherapy. Investors care because TNBC drives demand for novel drugs, influences clinical trial risk and regulatory milestones, and can significantly affect the valuation of biotech and pharma companies working on treatments.
objective response rate medical
"83% objective response rate (one complete response, four partial responses)"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
serious adverse events medical
"with no paxalisib-related serious adverse events"
Serious adverse events are significant problems or negative outcomes that occur during a medical treatment or clinical trial, such as severe side effects, hospitalizations, or life-threatening conditions. They matter to investors because such events can impact a company's reputation, lead to regulatory scrutiny, or delay the development of new products, ultimately affecting the company’s financial performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SYDNEY, Nov. 19, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended June 30, 2026 with the U.S. Securities and Exchange Commission ("SEC").

Kazia Therapeutics Limited Logo

The Annual Report, which includes the Company's audited consolidated financial statements for fiscal year 2026, is available on the Company's website and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of the Annual Report, including the Company's audited consolidated financial statements, free of charge upon request.

Fiscal 2026 Financial Highlights

  • Cash, cash equivalents and short-term investments of approximately A$61.2 million as of 30 June 2026.
  • The Company believes that its working capital, together with the net proceeds of the August 2026 public offering and the Sovargen milestone payment received in September 2026, is sufficient to fund its planned operations for at least the next 12 months from the date of the Annual Report.

Recent Highlights

  • Encouraging initial Stage IV TNBC data: 100% clinical benefit rate and 83% objective response rate (one complete response, four partial responses) in six evaluable patients treated with paxalisib-based regimens, with no paxalisib-related serious adverse events. Median reductions of 83% in metastasis-associated CTC clusters and 51% in terminally exhausted CD8+ T cells.
  • Oversubscribed public offering of up to US$120 million: Approximately US$40 million in upfront gross proceeds, with up to approximately US$80 million in additional gross proceeds from milestone-linked warrants tied to the Stage IV TNBC data readout (expected 2H 2027) and the HR+/HER2- data readout (expected 1H 2028).
  • Pipeline expanded into additional indications: Advancing a three-arm HR+/HER2- breast cancer expansion of the ongoing trial and a planned five-arm Phase 2 study in MSS/pMMR colorectal cancer, with CRC enrollment expected to commence in Q1 2027.
  • Clinical advancement across additional paxalisib programs: First patients dosed in two additional paxalisib trials – PNOC035 Arm A (paxalisib plus gemcitabine in recurrent or progressive pediatric AT/RT) and partner Sovargen's Phase 1b/2a trial in rare mTORopathy-related epilepsies, the latter triggering a US$2 million milestone payment to Kazia.
  • Expanded intellectual property portfolio supporting paxalisib's clinical development: Filed three provisional patent applications covering a perioperative treatment strategy in high-risk TNBC, resensitization of CDK4/6 inhibitor-resistant HR+/HER2− breast cancer, and therapeutic applications in MSS/pMMR colorectal cancer. The perioperative TNBC filing was supported by preclinical findings demonstrating a 95% reduction in residual disease and local recurrence (p<0.0001) following neoadjuvant chemo-immunotherapy and surgery.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance. Kazia's lead asset, paxalisib, is an investigational oral, brain-penetrant dual PI3K/mTOR inhibitor being developed across multiple forms of cancer, including cancers of the central nervous system, advanced breast cancer and colorectal cancer. Paxalisib has received U.S. FDA Fast Track and Orphan Drug designations for glioblastoma, Fast Track designation for PI3K-altered brain metastases with radiation and Rare Pediatric Disease and Orphan Drug designations for select pediatric brain tumors, including diffuse intrinsic pontine glioma and atypical teratoid/rhabdoid tumor.

Kazia is also advancing two potentially first-in-class preclinical programs: NDL2, a nuclear PD-L1 protein degrader designed to address mechanisms of immunotherapy resistance and metastatic progression, and MSETC, a SETDB1 inhibitor intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Additionally, Kazia's portfolio includes EVT801, a small molecule VEGFR-3 inhibitor that the Company is exploring for potential partnering opportunities. For more information, visit www.kaziatx.com, as well as follow us on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identified by words such as "anticipates," "believes," "expects," "intends," "plans," "may," "will," "could," "should," "estimates," "projects," "potential," "suggests," and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: the sufficiency of the Company's cash, cash equivalents and short-term investments to fund its planned operations; the timing, design, initiation, enrollment, completion and data readouts of the Company's ongoing and planned clinical trials, including in Stage IV TNBC, HR+/HER2- breast cancer and MSS/pMMR colorectal cancer; the potential exercise of the Series A and Series B warrants issued in the August 2026 public offering and any related proceeds; the potential therapeutic benefits and development of paxalisib, NDL2, MSETC and EVT801; the Company's intellectual property strategy and provisional patent applications; and the activities of the Company's collaborators, including Sovargen.

These forward-looking statements are based on management's current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the preliminary nature of early-stage clinical data, which may change as more patient data become available; the risk that results of preclinical and translational studies may not be predictive of results in clinical trials in humans; risks associated with the research and development of therapeutic programs; the timing, conduct and enrollment of the Company's clinical trials; whether any Series A or Series B warrants will be exercised; regulatory review and approval processes; the Company's need to raise substantial additional capital and its ability to obtain sufficient funding to advance its programs; reliance on third-party collaborators, contract research organizations and trial sites; the Company's ability to obtain, maintain and protect its intellectual property; competition; general economic and market conditions; and the Company's ability to maintain compliance with Nasdaq listing requirements.

For a more complete discussion of risks and uncertainties, please refer to the Company's filings with the SEC, including the "Risk Factors" section of the Company's most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-filing-of-annual-report-on-form-20-f-for-fiscal-year-ended-june-30-2026-302944715.html

SOURCE Kazia Therapeutics Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kazia Therapeutics report in its initial stage IV triple-negative breast cancer data?

Paxalisib-based regimens showed 100% clinical benefit and an 83% objective response rate in six evaluable patients. The responses included one complete response and four partial responses. No serious adverse events were attributed to paxalisib.

When are the trial readouts tied to Kazia Therapeutics' public offering warrants expected?

Kazia expects the warrant-linked readouts in 2H 2027 for stage IV triple-negative breast cancer and 1H 2028 for hormone receptor-positive, HER2-negative breast cancer. The warrants could generate up to approximately US$80 million in additional gross proceeds.

How can shareholders get Kazia Therapeutics' fiscal 2026 annual report?

Shareholders can request a free printed copy of the annual report, including the audited consolidated financial statements. The report is also available on Kazia's website and the SEC's website.

Keep reading